Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Binkui Li

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
BMC Cancer|December 1, 2018
Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablationWenwu Liu, Yun Zheng, Ruhai Zou, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|April 28, 2012
Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissuesPinzhu Huang, Jiliang Qiu, Jinghong You, et al.
Clinical and Experimental Medicine|June 28, 2024
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinomaZhenkun Huang, Tiejun Chen, Wenbin Li, et al.
Journal of Translational Medicine|September 30, 2011
Identification of MACC1 as a novel prognostic marker in hepatocellular carcinomaJiliang Qiu, Pinzhu Huang, Qian Liu, et al.
Journal of Cancer|August 21, 2018
Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma RecurrenceQiang Tao, Wei He, Binkui Li, et al.
International Immunopharmacology|July 19, 2024
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort studyZhenkun Huang, Tiejun Chen, Wenbin Li, et al.
Clinical Biochemistry|March 8, 2011
Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomyPinzhu Huang, Jiliang Qiu, Binkui Li, et al.
Oncology Letters|March 31, 2017
Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrenceYadi Liao, Yun Zheng, Wei He, et al.
Cell Death Discovery|November 28, 2023
METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibitionFangfang Bi, Yuxiong Qiu, Zongfeng Wu, et al.
Journal of Clinical Gastroenterology|January 8, 2015
Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma: A Prospective, Randomized Controlled Clinical TrialXianqiu Wu, Binkui Li, Jiliang Qiu, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
BMC Cancer|December 1, 2018
Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablationWenwu Liu, Yun Zheng, Ruhai Zou, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|April 28, 2012
Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissuesPinzhu Huang, Jiliang Qiu, Jinghong You, et al.
Clinical and Experimental Medicine|June 28, 2024
PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinomaZhenkun Huang, Tiejun Chen, Wenbin Li, et al.
Journal of Translational Medicine|September 30, 2011
Identification of MACC1 as a novel prognostic marker in hepatocellular carcinomaJiliang Qiu, Pinzhu Huang, Qian Liu, et al.
Journal of Cancer|August 21, 2018
Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma RecurrenceQiang Tao, Wei He, Binkui Li, et al.
International Immunopharmacology|July 19, 2024
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort studyZhenkun Huang, Tiejun Chen, Wenbin Li, et al.
Clinical Biochemistry|March 8, 2011
Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomyPinzhu Huang, Jiliang Qiu, Binkui Li, et al.
Oncology Letters|March 31, 2017
Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrenceYadi Liao, Yun Zheng, Wei He, et al.
Cell Death Discovery|November 28, 2023
METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibitionFangfang Bi, Yuxiong Qiu, Zongfeng Wu, et al.
Journal of Clinical Gastroenterology|January 8, 2015
Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma: A Prospective, Randomized Controlled Clinical TrialXianqiu Wu, Binkui Li, Jiliang Qiu, et al.
Pageof 9